Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Silence Therapeutics



Unlock datapoints

Portfolio analytics


News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 1
Average round size
The average size of a deal this fund participated in
Portfolio companies 1
Rounds per year 0.05
Lead investments 1
Exits 1
Key employees Soon

Areas of investment

  • Pharmaceutical
  • Biotechnology
  • Nanotechnology

Silence Therapeutics appeared to be the Corporate Investor, which was created in 1999. The company was established in Europe in United Kingdom. The main office of represented Corporate Investor is situated in the London.

We can highlight the next thriving fund investment areas, such as Electronics, Biotechnology. Besides, a startup needs to be aged 11-15 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Arrowhead Pharmaceuticals.

The fund is generally included in less than 2 deals every year. The usual things for fund are deals in the range of 5 - 10 millions dollars. The increased amount of exits for fund were in 2000. The high activity for fund was in 2017.

The standard case for the fund is to invest in rounds with 1 partaker. Despite the Silence Therapeutics, startups are often financed by RA Capital Management, OrbiMed.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Silence Therapeutics:
Typical Co-investors
Silence Therapeutics is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Silence Therapeutics:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
ACG Equity Partners Charleston, South Carolina, United States
Adcock Private Equity -
Capture Investments -
China Trends Holdings China, Hong Kong, Hong Kong Island Japan, Tokyo
Ericsson Ventures California, Santa Clara, United States
Expara IDM Ventures Central, Central Region, Singapore
Fellowes Illinois, Itasca, United States
Glaxo Group Brentford, Hounslow, United Kingdom
Lee Prize for Innovation and Entrepreneurship Las Vegas, Nevada, United States
Micromanagement Ventures New York, New York, United States
NDFOS Seoul, Seoul-t'ukpyolsi, South Korea
Octava Georgia, Norcross, United States
S.A.C. Capital Advisors Connecticut, Stamford, United States
Sino-Ocean Group Beijing, Beijing, China
Titanium Investments Moscow, Moscow, Russia
Yamaguchi Bank Japan, Shimonoseki, Yamaguchi Prefecture
Yaotian Keji Beijing, China, Pinggu


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Silence Therapeutics?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 1
Average round size 9M
Rounds per year 0.05
Peak activity year 2017
Lead investments 1
Exits 1
Crunchbase icon

Content report

The following text will be sent to our editors: